IAR025, a novel anti-DLL3 x CD3-bispecific antibody, displays high antitumor efficacy in preclinical models of small-cell lung cancer

Abstract Small-cell lung cancer (SCLC) is one of the most aggressive subtype of lung carcinoma with limited treatment options. Delta-like ligand 3 (DLL3), a Notch ligand protein, has been an attractive target for SCLC due to its high expression on SCLC but limited expression on normal tissues. Here,...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yang Liu, Lei Cao, Mengqiu Xu, Ninghuan Li, Jian Zhang, Mengjia Zhu, Zhihui Kuang, Huijun Sha, Min Wu, Jinling Xu, Zhihai Wu, Ye Feng, Li Li
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer 2026-05-01
coleção:	Cancer Immunology, Immunotherapy
Assuntos:	DLL3 T-cell engager Bispecific antibody Small-cell lung cancer Combination therapy
Acesso em linha:	https://doi.org/10.1007/s00262-026-04416-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!